Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
38.37
Aug 21 • 3:59 PM ET Dollar change+1.24 Percentage change(3.34%)
Aftermarket Close
38.37
Aftermarket • 7:30 PM ET Dollar change0.00 Percentage change(0.00%)
Index
RUT
Market Cap
1.70B
Enterprise Value
1.37B
Income
-
Sales
-
Book/sh
8.99
Cash/sh
7.95
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
50
IPO
Apr 30, 2026
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
4.27
P/C
4.83
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
33.10
Current Ratio
33.10
Debt/Eq
0.04
LT Debt/Eq
0.04
Option/Short
No / Yes
EPS (ttm)
-
EPS next Y
-2.94
EPS next Q
-0.71
EPS this Y
17.24%
EPS next Y
5.61%
EPS next 5Y
6.05%
EPS past 3/5Y
- -
Sales past 3/5Y
- -
EPS Y/Y TTM
-
Sales Y/Y TTM
-
EPS Q/Q
-
Sales Q/Q
-
Insider Own
45.95%
Insider Trans
7.32%
Inst Own
65.14%
Inst Trans
164.66%
ROA
-
ROE
-
ROIC
-
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
13.81%
SMA50
23.58%
SMA200
27.91%
Trades
Shs Outstand
44.33M
Shs Float
26.64M
52W High
40.17 -4.48%
52W Low
24.15 58.88%
Volatility
6.90% 7.16%
ATR (14)
2.45
RSI (14)
66.25
Beta
-
Rel Volume
0.49
Avg Volume
328.05K
Volume
159,511
Perf Week
-2.24%
Perf Month
29.06%
Perf Quarter
35.06%
Perf Half Y
-
Perf YTD
47.58%
Perf Year
-
Perf 3Y
-
Perf 5Y
-
Perf 10Y
-
Prev Close
37.13
Price
38.37
Change %
3.34%
Date Action Analyst Rating Change Price Target Change
May-26-26Initiated Morgan Stanley Overweight $53
May-26-26Initiated Jefferies Buy $52
May-26-26Initiated Guggenheim Buy $80
May-26-26Initiated Evercore ISI Outperform $51
Avalyn Pharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). The company was founded by Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar on May 27, 2011 and is headquartered in Boston, MA.
CEOMs. Lyn Baranowski
CFO & Chief Business OfficerMr. Douglas R. Carlson
Ph.D.Dr. Melissa Rhodes DABT
Chief Medical OfficerDr. Howard M. Lazarus M.D.
Senior Director of IR & Corporate CommunicationsMs. Cassie Saitow
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novo Holdings A/S10% OwnerMay 01 '26Buy18.00555,5559,999,9903,883,289May 05 04:15 PM
Carroll JillDirectorMay 01 '26Buy18.00277,7785,000,0042,186,562May 01 06:50 PM
SR ONE CAPITAL MANAGEMENT, LLC10% OwnerMay 01 '26Buy18.00555,5559,999,9902,186,562May 01 06:46 PM